Roy Baynes, Merck Research Laboratories CMO (file photo)

With at least one gas­tric can­cer ap­proval on the line, Mer­ck­'s Keytru­da scores nod for ear­ly pa­tients in chemo com­bo

Big drug­mak­ers such as Mer­ck and Bris­tol My­ers Squibb are on the fir­ing line with the FDA over ac­cel­er­at­ed on­col­o­gy ap­provals that don’t ace their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.